ArticleBioMed research international2026
Usefulness of Molecular Diagnostic Kits for Detecting Helicobacter pylori Infection in Patients Receiving Proton Pump Inhibitors and Potassium-Competitive Acid Blockers.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Usefulness of Molecular Diagnostic Kits for Detecting Helicobacter pylori Infection in Patients Receiving Proton Pump Inhibitors and Potassium-Competitive Acid Blockers.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundHelicobacter pylori infection is associated with gastric cancer; therefore, therapies that eradicate H. pylori are crucial for its prevention. This study investigated the effects of clarithromycin (CAM)-resistance gene mutations on the success rate of H. pylori eradication and the usefulness of the Smart Gene H. pylori G (Mizuho Medy Co. Ltd., Saga, Japan) molecular diagnostic kit for H. pylori infection, which detects CAM-resistance mutations.
methodsThis study enrolled patients who underwent esophagogastroduodenoscopy, during which intragastric fluid was collected. The Smart Gene kit was used to diagnose H. pylori infection and CAM-resistance mutations, and results were compared with those of the conventional urea breath test (UBT) and real-time polymerase chain reaction (PCR) results.
resultsThe study included 253 patients. H. pylori infection was confirmed by real-time PCR in 23 (9.1%) patients, and 99 (39.1%) patients were receiving a proton pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB). The sensitivities and specificities of the Smart Gene test and UBT were 87.0% and 82.6%, as well as 99.6% and 93.0%, respectively. PPI/P-CAB use did not affect the distribution of H. pylori DNA levels measured by real-time PCR, but the UBT values were significantly lower in the medicated group than in the unmedicated group (p < 0.05). Thirteen patients underwent treatment to eradicate H. pylori, with successful eradication in 11 (84.6%). The Smart Gene test identified three patients with CAM-resistance mutations. One patient was successfully treated with a metronidazole-based regimen, whereas CAM-based eradication therapy failed in two patients.
conclusionsThe Smart Gene molecular diagnostic test using intragastric fluid was useful for patients requiring PPI/P-CAB to manage gastrointestinal symptoms. It could also confirm an H. pylori infection and CAM-resistance mutations within 1 h of testing. This diagnostic test may help reduce side effects and the emergence of resistant strains due to unnecessary eradication therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.